Results 31 to 40 of about 28,818 (194)
Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors. [PDF]
, 2016 PurposeTo determine the maximum tolerated dose (MTD), toxicities, and pharmacodynamics effects of sirolimus combined with oral metronomic topotecan and cyclophosphamide in a pediatric population.Materials and methodsPatients who were 1 to 30 years of age
Allen, Shelly +9 more
core +1 more source
Ovarian Toxicity from Sirolimus [PDF]
New England Journal of Medicine, 2012 Low-dose oral sirolimus appears to increase the risk of menstrual-cycle disturbances and ovarian cysts. Monitoring patients for sirolimus-associated ovarian toxicity may be considered.
Braun Matthias +5 more
openaire +3 more sources
Hematology Reports, 2023 The β-thalassemias are a group of monogenic hereditary hematological disorders caused by deletions and/or mutations of the β-globin gene, leading to low or absent production of adult hemoglobin (HbA).
Maria Rita Gamberini +5 more
doaj +1 more source
Sirolimus-tacrolimus combination immunosuppression [PDF]
The Lancet, 2000 A series of 32 recipients of liver, kidney, or pancreas transplants who were treated with sirolimus and low-dose tacrolimus experienced a low rate of rejection and excellent graft function without drug-related toxic effects.
McAlister, Vivian C. +5 more
openaire +7 more sources
Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma
Frontiers in Pharmacology, 2021 Sirolimus is an effective oral treatment for pediatric patients with lymphangioma. The present clinical study in 15 children (0.12–16.39 years of age) examines the effects of underlying factors on sirolimus concentrations through application of a ...
Xiao Chen +8 more
doaj +1 more source
Experimental rat models of chronic allograft nephropathy: a review [PDF]
, 2014 Chronic allograft nephropathy (CAN) is the leading cause of late allograft loss after renal transplantation (RT), which continues to remain an unresolved problem. A rat model of CAN was first described in 1969 by White et al. Although the rat model of RT
Haylor, John, Shrestha, Badri
core +2 more sources
Posttransplant anemia: the role of sirolimus [PDF]
Kidney International, 2009 Posttransplant anemia is a common problem that may hinder patients' quality of life. It occurs in 12 to 76% of patients, and is most common in the immediate posttransplant period. A variety of factors have been identified that increase the risk of posttransplant anemia, of which the level of renal function is most important.
Arjang Djamali +5 more
openaire +3 more sources
Journal of Lipid Research, 2002 Sirolimus (Rapammune®, rapamycin, RAPA) is a potent immunosuppressive drug that reduces renal transplant rejection. Hyperlipidemia is a significant side effect of sirolimus treatment, and frequently leads to cardiovascular disease.
Joel D. Morrisett +9 more
doaj +1 more source
Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. [PDF]
, 2014 Understanding genetic aberrations in cancer leads to discovery of new targets for cancer therapies. The genomic landscape of hepatocellular carcinoma (HCC) has not been fully described. Therefore, patients with refractory advanced/metastatic HCC referred
Janku, Filip +4 more
core +3 more sources
Repurposing metformin for cancer treatment: current clinical studies. [PDF]
, 2016 In recent years, several studies have presented evidence suggesting a potential role for metformin in anti-cancer therapy. Preclinical studies have demonstrated several anticancer molecular mechanisms of metformin including mTOR inhibition, cytotoxic ...
Altman, Jessica K +10 more
core +1 more source